AUTHORS
Aaron T. Gerds, MD, MS, Andrew T Kuykendall, MD2, Ghaith Abu-Zeinah I, MD3, Rupali Roy Roy Bhave, MD4, Brian Chernak, MD5, Eunice Sue Wang, MD6, Anthony Michael Hunter, MD7, Shivani Handa, MD8, Kathryn Johnson, DNP9, Heidi Kosiorek, MS10, Amylou C Dueck, PhD11, Carolyn Mead-Harvey, MS12, Gillian Sanchez13, Raajit K. Rampal, MD, PhD14, Ruben Mesa, MD15, Ronald Hoffman, MD16, John O. Mascarenhas, MD17, Marina Kremyanskaya, MD, PhD18
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 Weill Cornell Medicine, New York, New York, United States
4 Atrium Health Wake Forest Baptist, Winston Salem, North Carolina, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
8 The Ohio State University Wexner Medical Center, columbus, Ohio, United States
9 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
10 Mayo Clinic Scottsdale, Scottsdale, United States
11 Mayo Clinic Scottsdale, Scottsdale, United States
12 Mayo Clinic Scottsdale, Scottsdale, United States
13 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Atrium Health Wake Forest Baptist, Winston Salem, North Carolina, United States
16 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
17 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
18 Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
ABSTRACT
Introduction. Myelofibrosis (MF) is characterized by a chronic inflammatory state in which elevated circulating cytokines contribute to disease progression and adverse clinical outcomes. Interleukin-8 (IL-8/CXCL8) has emerged as a particularly important mediator, with higher plasma levels associated with more aggressive disease features and inferior leukemia-free survival. (Dunbar et al. Blood 2023). Preclinical studies demonstrate that IL-8 signaling through its receptors, CXCR1 and CXCR2, promotes proliferation of MF hematopoietic progenitors, while pharmacologic blockade with the CXCR1/2 inhibitor reparixin reduces colony formation. In murine models, genetic disruption of CXCR2 improves hematologic parameters, splenomegaly, and survival. (Verachi et al. Front Oncol. 2022). These findings provide a strong rationale for therapeutic inhibition of CXCR1/2 with reparixin in patients with MF.
Methods. NCT05835466 is an ongoing Myeloproliferative Neoplasm Research Consortium (MPN-RC) open-label, phase 2 study of reparixin in patients (pts) with MF. Pts with MF previously treated with or ineligible to receive a JAK inhibitor were enrolled. Reparixin was given orally at a dose of 1200mg TID on days 1-28 of 28-day cycles. Primary response assessment occurred at week 24 following cycle 6. Responding pts could continue to receive reparixin.
Eligible pts had platelets ≥25 x109/L and were treatment refractory for ≥3 months with persistent palpable splenomegaly ≥ 5cm or symptoms related to splenomegaly), or intolerant), or in the Investigator's judgment, were not candidates for an approved JAKi.
The primary endpoint was IWG-MRT/ELN overall response rate (CR, PR, or clinical improvement) at 24 weeks (cycle 7). A Bayesian optimal phase 2 (BOP2) design was used with an interim analysis performed after 10 pts.
Results. 10 pts were enrolled, 9 having received treatment, and one in screening at the time of analysis. Of the 9 pts on treatment, the median age was 73y (range: 58-88y). Eight (89%) patients had received prior ruxolitinib. Seven (78%) had intermediate-2 or high-risk disease by DIPSS. Median time since MF diagnosis was 73.5 months (range: 30.3-312.7). Median hemoglobin was 8.9 g/dL (range: 6.3-11.8 g/dL), median platelet count was 151 x 109/L (range: 39-374 x 109/L). Three pts were transfusion dependent. Median MF-SAF TSS at baseline was 8 (range: 6-37). Median spleen volume at baseline was 982 cm3 (range: 166-2393 cm3).
Pts received a median of 2 cycles (range: 1-17). At the time of analysis, 3 pts remained on study, while 6 discontinued treatment because of: adverse events or toxicity (n=2), patient withdrawal (n=2), disease progression (n=1), or loss to follow-up (n=1). Two pts were evaluable for the primary response assessment; both had stable disease. Of note, one of these pts experienced a 26% reduction in spleen volume (1262 to 933 cm3) and remained on therapy through 17 cycles with ongoing disease control. Treatment was generally associated with stable hematologic parameters. Patient Global Impression of Change (PGIC) at week 24 demonstrated one pt reporting "much improved" and one reporting "minimally improved."
Adverse events (AEs) were predominantly grade 1–2. The most common treatment-emergent AEs included diarrhea (33%), fatigue (33%), nausea (33%), headache (22%), pruritus (22%), rash (22%), chills (22%), hypoalbuminemia (22%), and hypocalcemia (22%). One case of progressive multifocal leukoencephalopathy occurred and was attributed unlikely related to study treatment. Grade ≥3 AEs were infrequent; three grade 3 cardiac AEs occurred. However, protocol-defined toxicity stopping boundaries were not crossed.
Conclusion. The interim analysis demonstrates that reparixin monotherapy has an expected and manageable safety profile but limited objective responses in heavily pretreated MF population. Unlike many other MF directed therapies, reparixin treatment did not cause worsening cytopenias. Disease stabilization and meaningful spleen volume reduction were observed in one pt receiving prolonged therapy. Additional cardiac monitoring will be incorporated into a forthcoming amendment.
Enrollment of the 10th participant is ongoing, and updated efficacy, safety, and correlative biomarker analyses will be presented. Following the establishment of a safety profile in this population, part 2, with combination therapy in pts with suboptimal responses to JAK inhibitors will be initiated.
DISCLOSURES
Marina Kremyanskaya, MD, PhD: Kura - Honoraria; PharmaEssentia - Honoraria; Dompe - Research Funding; Kura - Consultancy (Includes expert testimony); Agios - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Silence - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Protagonist - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); PharmaEssentia - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Cogent - Consultancy (Includes expert testimony)